Rioprostil, a new Prostaglandin E₁ Analogue, in the Once-Daily Treatment for the Prevention of Duodenal Ulcer Recurrence: A Comparison with Ranitidine

Abstract

Businger J A, Fumagalli I, Michel H, Delas N, Stocker H. Rioprostil, a new prostaglandin E] analogue, in the once-daily treatment for the prevention of duodenal ulcer recurrence: a comparison with ranitidine. Scand J Gastroenterol 1989,24(suppl 164), 152-160

The efficacy of Rioprostil^® (a new prostaglandin E, analogue) is compared with that of ranitidine in the recurrence prevention of duodenal ulcer(s). Duration of treatment is 6 months. Ninety-seven patients received rioprostil, 600 μg once-daily orally, and 110 patients received ranitidine, 150 mg once-daily orally. On rioprostil, 14.9% of patients showed a relapse after 6 months compared to 10.1 % on ranitidine. Diarrhoea occurred in 7 patients on rioprostil and 3 patients on ranitidine. Rioprostil given 600 μg daily in the evening is a highly effective treatment for the prevention of duodenal ulcer relapse, the efficacy not being significantly different from ranitidine 150 mg.

Key Words:

• Duodenal ulcer recurrence prevention prostaglandin E₁
• rioprostil